Skip to main content
Journal cover image

Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation.

Publication ,  Journal Article
Durham, TA; Hassmiller Lich, K; Viera, AJ; Fine, JP; Mukherjee, J; Weinberger, M; Dusetzina, SB
Published in: Am J Cardiol
November 15, 2017

New oral anticoagulants (OACs) and updated risk stratification have the potential to improve the quality of care for patients with atrial fibrillation (AF). To describe the time from AF diagnosis to the initiation of an OAC, characteristics associated with treatment, and the incidence of switching OACs, we conducted this retrospective cohort study of 23,018 adults with incident AF receiving care between 2010 and 2014 in 647 primary care practices participating in the United Kingdom Clinical Practice Research Datalink. In patients with moderate to high stroke risk (CHA2DS2-VASc ≥ 2), the median time from diagnosis to OAC initiation decreased from 10 to 2 months. Among 980 at very low stroke risk (CHA2DS2-VASc = 0), 29% received OAC prescriptions after 90 days. Being prescribed an OAC was associated with a history of stroke or transient ischemic attack (relative risk 1.3); severe dementia or psychosis was most associated with not being prescribed an OAC (relative risk 0.3). After 1 year, the risk of OAC switching was higher for patients initiating dabigatran (19%) than warfarin (6%), rivaroxaban (8%), or apixaban (9%). The prescribing of OACs in moderate-to-high-risk patients in the United Kingdom increased annually; 1/3 of very low-risk patients were prescribed OACs contrary to guidance. In conclusion, future research should refine decision-making tools to minimize the unwanted effects of underutilization and overutilization of OACs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

November 15, 2017

Volume

120

Issue

10

Start / End Page

1820 / 1829

Location

United States

Related Subject Headings

  • United Kingdom
  • Time Factors
  • Survival Rate
  • Stroke
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Male
  • Incidence
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Durham, T. A., Hassmiller Lich, K., Viera, A. J., Fine, J. P., Mukherjee, J., Weinberger, M., & Dusetzina, S. B. (2017). Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. Am J Cardiol, 120(10), 1820–1829. https://doi.org/10.1016/j.amjcard.2017.07.091
Durham, Todd A., Kristen Hassmiller Lich, Anthony J. Viera, Jason P. Fine, Jayanti Mukherjee, Morris Weinberger, and Stacie B. Dusetzina. “Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation.Am J Cardiol 120, no. 10 (November 15, 2017): 1820–29. https://doi.org/10.1016/j.amjcard.2017.07.091.
Durham TA, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger M, et al. Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. Am J Cardiol. 2017 Nov 15;120(10):1820–9.
Durham, Todd A., et al. “Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation.Am J Cardiol, vol. 120, no. 10, Nov. 2017, pp. 1820–29. Pubmed, doi:10.1016/j.amjcard.2017.07.091.
Durham TA, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger M, Dusetzina SB. Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. Am J Cardiol. 2017 Nov 15;120(10):1820–1829.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

November 15, 2017

Volume

120

Issue

10

Start / End Page

1820 / 1829

Location

United States

Related Subject Headings

  • United Kingdom
  • Time Factors
  • Survival Rate
  • Stroke
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Male
  • Incidence
  • Humans